Terns Pharmaceuticals Stock Forecast, Price & News

-1.19 (-6.29 %)
(As of 04/12/2021 04:46 PM ET)
Today's Range
Now: $17.74
50-Day Range
MA: $22.02
52-Week Range
Now: $17.74
Volume75,438 shs
Average Volume205,242 shs
Market Capitalization$445.72 million
P/E RatioN/A
Dividend YieldN/A
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.
Terns Pharmaceuticals logo

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:TERN
Phone650 525 5535
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$445.72 million
Next Earnings Date6/29/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

2.03 out of 5 stars

Medical Sector

51st out of 2,011 stocks

Biotechnology Industry

4th out of 143 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-1.19 (-6.29 %)
(As of 04/12/2021 04:46 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TERN News and Ratings via Email

Sign-up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Terns Pharmaceuticals (NASDAQ:TERN) Frequently Asked Questions

Is Terns Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terns Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Terns Pharmaceuticals stock.
View analyst ratings for Terns Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Terns Pharmaceuticals?

Wall Street analysts have given Terns Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Terns Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Terns Pharmaceuticals' next earnings date?

Terns Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, June 29th 2021.
View our earnings forecast for Terns Pharmaceuticals

How were Terns Pharmaceuticals' earnings last quarter?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) issued its earnings results on Monday, March, 29th. The company reported ($30.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by $30.03.
View Terns Pharmaceuticals' earnings history

What price target have analysts set for TERN?

3 equities research analysts have issued 1 year price objectives for Terns Pharmaceuticals' stock. Their forecasts range from $29.00 to $32.00. On average, they expect Terns Pharmaceuticals' share price to reach $30.50 in the next year. This suggests a possible upside of 71.9% from the stock's current price.
View analysts' price targets for Terns Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Terns Pharmaceuticals' key executives?

Terns Pharmaceuticals' management team includes the following people:
  • Dr. Weidong Zhong Ph.D., Co-Founder, Chairman & Chief Scientific Officer (Age 55)
  • Mr. Senthil Vel Sundaram, CEO & Director (Age 43, Pay $358.33k)
  • Dr. Erin Quirk M.D., Pres & Chief Medical Officer (Age 50, Pay $495.07k)
  • Dr. Mark Joseph Vignola, Chief Financial Officer (Age 43, Pay $330k)
  • Mr. Seokho Yoon Esq., COO & Gen. Counsel (Age 43)

Who are some of Terns Pharmaceuticals' key competitors?

When did Terns Pharmaceuticals IPO?

(TERN) raised $101 million in an IPO on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

What is Terns Pharmaceuticals' stock symbol?

Terns Pharmaceuticals trades on the NASDAQ under the ticker symbol "TERN."

When does Terns Pharmaceuticals' lock-up period expire?

Terns Pharmaceuticals' lock-up period expires on Wednesday, August 4th. Terns Pharmaceuticals had issued 7,500,000 shares in its initial public offering on February 5th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. After the expiration of Terns Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Terns Pharmaceuticals?

Shares of TERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Terns Pharmaceuticals' stock price today?

One share of TERN stock can currently be purchased for approximately $17.74.

How much money does Terns Pharmaceuticals make?

Terns Pharmaceuticals has a market capitalization of $445.72 million.

What is Terns Pharmaceuticals' official website?

The official website for Terns Pharmaceuticals is

How can I contact Terns Pharmaceuticals?

The company can be reached via phone at 650 525 5535.

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.